Recent clinical evidence shows that semaglutide, a GLP-1 receptor agonist, preferentially reduces visceral fat deposits while preserving lean muscle mass
For weight management specifically, semaglutide (Wegovy, also approved for adolescents 12 years), liraglutide 3 mg (Saxenda), and tirzepatide (Zepbound) have received FDA approval
This means that their findings may not be fully generalizable to other settings. They also note that their records only show whether a medication was dispensed to a patient and not whether they took it as prescribed
Summary: GLP-1 receptor agonists may reduce alcohol consumption in some individuals, but they are not approved for treating alcohol use disorder and evidence remains preliminary
It is usually safe to switch from semaglutide to tirzepatide, and research shows that it might even help with weight loss
Common Side Effects of Semaglutide Semaglutide is a medication often prescribed to help with weight loss or to manage type 2 diabetes